Literature DB >> 1692157

The neuropeptide substance P stimulates production of interleukin 1 in human blood monocytes: activated cells are preferentially influenced by the neuropeptide.

M A Laurenzi1, M A Persson, C J Dalsgaard, A Haegerstrand.   

Abstract

Substance P (SP) has recently been reported to induce interleukin 1 (IL-1) production by human monocytes. This was confirmed in our experiments with human monocytes cultivated in the presence of SP or SP together with lipopolysaccharide (LPS). In addition, a wide variability of cell response to the neuropeptide was noticed. Three out of twelve cell cultures were directly stimulated by SP to release IL-1, while four additional cultures needed prestimulation with suboptimal doses of LPS, and no effect was seen in the five remaining experiments. The data may suggest that preferentially activated monocytes respond to SP. The production of IL-1 by SP-stimulated monocytes is of great interest considering the broad spectrum of activity of IL-1 and the increasing evidence of sensory neuron involvement in acute and chronic inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1692157     DOI: 10.1111/j.1365-3083.1990.tb02801.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  23 in total

1.  Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes.

Authors:  J P Lai; W Z Ho; G X Zhan; Y Yi; R G Collman; S D Douglas
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Real-time reverse transcription-PCR quantitation of substance P receptor (NK-1R) mRNA.

Authors:  Jian-Ping Lai; Steven D Douglas; Yan-Jian Wang; Wen-Zhe Ho
Journal:  Clin Diagn Lab Immunol       Date:  2005-04

Review 3.  The significance of substance P in physiological and malignant haematopoiesis.

Authors:  Michal Nowicki; Danuta Ostalska-Nowicka; Beata Kondraciuk; Bogdan Miskowiak
Journal:  J Clin Pathol       Date:  2006-12-15       Impact factor: 3.411

4.  Tachykinins and Neurokinin Receptors in Bone Marrow Functions: Neural-Hematopoietic Link.

Authors:  Tilman E Klassert; Shyam A Patel; Pranela Rameshwar
Journal:  J Receptor Ligand Channel Res       Date:  2010-04-01

Review 5.  Leukemia inhibitory factor, a cytokine at the interface between neurobiology and immunology.

Authors:  P H Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

6.  Substance P enhances Th17 phenotype in individuals with generalized anxiety disorder: an event resistant to glucocorticoid inhibition.

Authors:  Priscila O Barros; Thais B Ferreira; Morgana M M Vieira; Carla Renata M Almeida; Carlos Fernando Araújo-Lima; Renato G Silva-Filho; Joana Hygino; Regis M Andrade; Arnaldo F Andrade; Cleonice A Bento
Journal:  J Clin Immunol       Date:  2010-09-24       Impact factor: 8.317

7.  Expression of calcitonin gene-related peptide in rat pulp and periodontal tissues by indirect immunofluorescence method.

Authors:  Yingming Sun; Rui Tao; Mengjie Zhang; Xue Cao; Hong Wang; Lufeng Xue; Meng Wu
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2013-12

8.  Substance P-stimulated interleukin-8 expression in human colonic epithelial cells involves Rho family small GTPases.

Authors:  Dezheng Zhao; Sabina Kuhnt-Moore; Huiyan Zeng; Amy Pan; Jack S Wu; Simos Simeonidis; Mary P Moyer; Charalabos Pothoulakis
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

9.  Endogenous substance P mediates cold water stress-induced increase in interleukin-6 secretion from peritoneal macrophages.

Authors:  G F Zhu; C Chancellor-Freeland; A S Berman; R Kage; S E Leeman; D I Beller; P H Black
Journal:  J Neurosci       Date:  1996-06-01       Impact factor: 6.167

10.  Elevated monocyte interleukin-6 (IL-6) production in immunosppressed trauma patients. II. Downregulation by IL-4.

Authors:  G Szabo; K Kodys; C L Miller-Graziano
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.